NIDA ARIF: Open Payments
NPI 1952867079 · SACRAMENTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,122 in 48 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $1,040 · 2025 $1,122
Food & beverage: $1,115Education: $7
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation | 15 | $301 |
| UCB, Inc. | 6 | $168 |
| Regeneron Healthcare Solutions, Inc. | 7 | $146 |
| Lilly USA, LLC | 3 | $96 |
| Galderma Laboratories, L.P. | 3 | $84 |
| Arcutis Biotherapeutics, Inc. | 3 | $61 |
| ABBVIE INC. | 3 | $53 |
| Novartis Pharmaceuticals Corporation | 2 | $52 |
| LEO Pharma Inc. | 2 | $47 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 1 | $44 |
Products named: OPZELURA, DUPIXENT, Bimzelx, TALTZ, NEMLUVIO, Zoryve, ADBRY, ILUMYA.
Industry payments across CA — which companies pay providers there.
